1.Improving Tuberculosis Medication Adherence: The Potential of Integrating Digital Technology and Health Belief Model
Mohd Fazeli SAZALI ; Syed Sharizman Syed Abdul RAHIM ; Ahmad Hazim MOHAMMAD ; Fairrul KADIR ; Alvin Oliver PAYUS ; Richard AVOI ; Mohammad Saffree JEFFREE ; Azizan OMAR ; Mohd Yusof IBRAHIM ; Azman ATIL ; Nooralisa Mohd TUAH ; Rahmat DAPARI ; Meryl Grace LANSING ; Ahmad Asyraf Abdul RAHIM ; Zahir Izuan AZHAR
Tuberculosis and Respiratory Diseases 2023;86(2):82-93
Tuberculosis (TB) is a significant public health concern. Globally, TB is among the top 10 and the leading cause of death due to a single infectious agent. Providing standard anti-TB therapy for at least 6 months is recommended as one of the crucial strategies to control the TB epidemic. However, the long duration of TB treatment raised the issue of non-adherence. Non-adherence to TB therapy could negatively affect clinical and public health outcomes. Thus, directly observed therapy (DOT) has been introduced as a standard strategy to improve anti-TB medication adherence. Nonetheless, the DOT approach has been criticized due to inconvenience, stigma, reduced economic productivity, and reduced quality of life, which ultimately could complicate adherence issues. Apart from that, its effectiveness in improving anti-TB adherence is debatable. Therefore, digital technology could be an essential tool to enhance the implementation of DOT. Incorporating the health belief model (HBM) into digital technology can further increase its effectiveness in changing behavior and improving medication adherence. This article aimed to review the latest evidence regarding TB medication non-adherence, its associated factors, DOT’s efficacy and its alternatives, and the use of digital technology and HBM in improving medication adherence. This paper used the narrative review methodology to analyze related articles to address the study objectives. Conventional DOT has several disadvantages in TB management. Integrating HBM in digital technology development is potentially effective in improving medication adherence. Digital technology provides an opportunity to improve medication adherence to overcome various issues related to DOT implementation.
2.Effectiveness of Mobile Application to Improve Adherence to Tuberculosis Treatment: A Study Protocol
Mohd Fazeli Sazali ; Syed Sharizman Syed Abdul Rahim ; Richard Avoi ; Nooralisa Mohd Tuah ; Roddy Teo ; Meryl Grace Lansing
Malaysian Journal of Medicine and Health Sciences 2023;19(No.6):347-354
Introduction: Tuberculosis (TB) is a leading cause of death due to a single infectious agent. The disease is treatable
by a minimum of six months of anti-TB drugs. However, prolonged duration of treatment using directly observed
therapy (DOT) causes significant inconvenience to patients and is ineffective in improving treatment outcomes.
Therefore, incorporating the Health Belief Model into the development of digital technology could help change
behaviour and improve adherence. This study aimed to determine the effectiveness of mobile applications in improving TB medication adherence. Methods: This study proposed to conduct a randomized trial among TB patients
in the Kota Kinabalu, Penampang, and Putatan districts of Sabah, Malaysia. The eligible sample will be randomly
assigned to the mobile application DOT arm and standard DOT arm. The primary outcome is the adherence level
calculated by the percentage of medication observed divided by the intended dose taken in two months, with 80%
and more successfully observed treatment considered highly adherent. The secondary outcomes are health-related
quality of life, satisfaction, and monthly household income. Multiple logistic regression and repeated measures
ANCOVA will be used to determine the effectiveness of interventions to achieve primary and secondary outcomes.
Discussion: The findings from this study could hopefully provide insight into rethinking TB care delivery to achieve
better TB treatment outcomes. Trial Registration: This study protocol has been approved by the Medical Research
Ethics Committee (MREC), Ministry of Health Malaysia (NMRR ID-21-01949-73X) and registered with ClinicalTrials.
gov (NCT05259254).